SMFR SEMA4 HLDGS CORP

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024. Management will host a conference call that day to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time. 

Conference Call Details 

Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at . 

About GeneDx 

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on , , , and . 

Investor Relations Contact: 

  

Media Contact: 

  



EN
04/04/2024

Underlying

SMFRSEMA4 HLDGS CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEMA4 HLDGS CORP

 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx Reports First Quarter 2024 Financial Results and Business Highl...

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMF...

April 29, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx Announces Partnership with Komodo Health to Expand Access to Wo...

GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry. The new partnership will increase access to GeneDx's...

April 23, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx to Report First Quarter 2024 Financial Results on Monday, April...

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024. Management will host a conference call that day to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.  Conference Call Details Investors interested in listening to the conference call are required to ...

April 4, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx to Present Data at the 2024 American College of Medical Genetic...

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. Across one platform presentation, an industry symposium and six poster presentations, including one selected as a ...

March 14, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx to Participate in 44th Annual Cowen Health Care Conference

GeneDx to Participate in 44th Annual Cowen Health Care Conference STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA. Management will participate in a fireside chat on Wednesday, March 6, 2024, at 10:30 a.m. ET. A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news...

February 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch